Efficacy of Slow Rate Ventriculolumbar Perfusion Chemotherapy for Leptomeningeal Carcinomatosis: Interim Result of a Phase II Study = Efficacy of Slow Rate Ventriculolumbar Perfusion Chemotherapy for Leptomeningeal Carcinomatosis: Interim Result of a Phase II Study

다국어 초록 (Multilingual Abstract)

Background To evaluate the efficacy of modified ventriculolumbar perfusion (VLP) chemotherapy with methotrexate on leptomeningeal carcinomatosis in terms of symptomatic response and side effects.
Methods Previous infusion rate of 20 mL/h was reduced to 15 mL/h for the purpose of decreasing constitutional side effects of VLP such as nausea/vomiting, insomnia and confusion. The primary outcome was the response rate of increased intracranial pressure (ICP), and the secondary outcome was the occurrence of side effects compared to previous 20 mL/h trial. This interim analysis to validate the reduced infusion rate is not to affect the original effect of VLP chemotherapy.
Results All forty-seven patients were enrolled including 22 patients with increased ICP. Thirteen patients out of these (59%) got normalized ICP after VLP chemotherapy. Moderate to severe (grade 2-3) confusion was observed in 3 patients (6%) and it was significantly reduced compared to those (23%) in the VLP 20 mL/h (p=0.017). Grade 2-3 nausea/vomiting was also reduced from 64% to 45% but failed to reach statistical significance (p=0.08). Median overall survival (OS) was 5.3 months (95% confidence interval, 3.55-7.05) and patients OS, who received maintenance VLP was significantly prolonged compared to patients who underwent induction VLP only (5.8 vs. 3.4 months, p=0.025).
Conclusion VLP of reduced perfusion rate (15 mL/h) showed compatible control rate of increased ICP at this interim analysis. Decreased moderate to severe side effects and prolonged OS in patients received maintenance VLP encourage us to evaluate the effectiveness of this trial further.

참고문헌 (Reference)

1 Bleyer WA, "“Concentration x time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms" 51 : 835-842, 1978

2 Gwak HS, "Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis:a Phase II Study" 19 : 1044-1045, 2014

3 Nakagawa H, "Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: a pilot study in 13 patients" 45 : 256-264, 1996

4 Gwak HS, "Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data" 36 : 491-499, 2013

5 Price RA, "The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy" 35 : 306-318, 1975

6 Debus OM, "Spontaneous central melatonin secretion and resorption kinetics of exogenous melatonin: a ventricular CSF study" 33 : 213-217, 2002

7 Chamberlain MC, "Radioisotope CSF flow studies in leptomeningeal metastases" 38 : 135-140, 1998

8 Chamberlain MC, "Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases" 46 : 1674-1677, 1996

9 Fleischhack G, "Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis" 44 : 1-31, 2005

10 Simon R, "Optimal two-stage designs for phase II clinical trials" 10 : 1-10, 1989

11 Sandberg DI, "Ommaya reservoirs for the treatment of leptomeningeal metastases" 47 : 49-54, 2000

12 Freilich RJ, "Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis" 38 : 51-57, 1995

13 Shapiro WR, "Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections" 293 : 161-166, 1975

14 Balis FM, "Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration" 45 : 259-264, 2000

15 Chamberlain MC, "Leptomeningeal metastases: a review of evaluation and treatment" 37 : 271-284, 1998

16 Taillibert S, "Leptomeningeal metastases from solid malignancy:a review" 75 : 85-99, 2005

17 Bruna J, "Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features" 115 : 381-389, 2009

18 Blasberg RG, "Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration" 61 : 633-641, 1977

19 Wasserstrom WR, "Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients" 49 : 759-772, 1982

20 Park JH, "Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era" 76 : 387-392, 2012

21 Gwak HS, "Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis" 153 : 1971-1978, 2011

22 Rubin RC, "Cerebrospinal fluid perfusion for central nervous system neoplasms" 16 : 680-692, 1966

23 Grossman SA, "Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography" 73 : 641-647, 1982

24 Chamberlain MC, "Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy" 55 : 506-512, 1998

25 Trotti A, "CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment" 13 : 176-181, 2003

26 Gwak HS, "Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer" 8 : 599-605, 2013

27 Yoon Hwan Byun, "A Novel Implantable Cerebrospinal Fluid Reservoir : A Pilot Study" 대한신경외과학회 61 (61): 640-644, 2018